文献速递胸部肿瘤放疗放疗物理与技术

非小细胞肺癌患者接受自适应放疗的生存获益

Survival benefits for non-small cell lung cancer patients treated with adaptive radiotherapy.
PubMed 文献 · Radiother Oncol · 2022-02-02

该回顾性研究纳入439例接受根治性放化疗的非小细胞肺癌患者,比较肿瘤匹配与自适应放疗(ART)开展前后两组的剂量学、生存及放射性肺炎。ART组计划靶区体积及肺、心脏平均剂量显著降低,9个月症状性及以上放射性肺炎显著减少,2年无进展生存从22%升至30%、总生存从43%升至56%。

要点

  • ART组计划靶区体积中位数由456 cm³降至270 cm³,肺与心脏平均剂量显著降低。
  • ART组9个月症状性放射性肺炎由50%降至20%,严重者由21%降至7%,致死性由6%降至0.4%。
  • ART组2年无进展生存由22%升至30%,总生存由43%升至56%,中位总生存由20个月延长至28个月。

核心结论

  • 肿瘤匹配与自适应放疗显著降低放射性肺炎,同时维持局部区域控制,并观察到无进展生存与总生存显著改善。

研究设计与样本

  • 回顾性研究纳入439例2010年至2018年接受根治性放化疗(50-66 Gy/25-33次)的连续非小细胞肺癌患者。
  • 患者分为肿瘤匹配与自适应放疗前组(pre-ART,184例)和开展后组(ART,255例),比较临床、治疗相关及剂量学变量。
  • 2013年起对放疗期间解剖变化显著的患者基于每日锥形束CT行肿瘤匹配与自适应放疗,此前每日锥形束CT与椎体匹配且未系统评估解剖变化。

主要发现

  • 两组分期(p=0.36)、组织学(p=0.35)、体能状态(p=0.12)及大体肿瘤体积(p=0.24)无显著差异,ART组同步化疗比例更高(78% vs 64%,p<0.001)。
  • 计划靶区体积中位数由pre-ART组456 [71;1262] cm³降至ART组270 [31;1166] cm³(p<0.001),肺平均剂量中位数由16.4 [1.9;24.7] Gy降至12.1 [1.7;19.4] Gy(p<0.001),心脏平均剂量中位数由8.0 [0.1;32.1] Gy降至4.4 [0.1;33.9] Gy(p<0.001)。
  • 9个月放射性肺炎发生率ART组显著降低:症状性(≥G2)由50%降至20%,严重(≥G3)由21%降至7%,致死性(G5)由6%降至0.4%,均p<0.001。
  • 2年无进展生存由pre-ART组22%升至ART组30%,总生存由43%升至56%,中位总生存由20个月延长至28个月。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Tumor match and adaptive radiotherapy based on on-treatment imaging increases the precision of RT. This allows a reduction of treatment volume and, consequently, of the dose to organs at risk. We investigate the clinical benefits of tumor match and adaptive radiotherapy for a cohort of non-small cell lung cancer patients (NSCLC). METHODS: In 2013, tumor match and adaptive radiotherapy based on daily cone-beam CT scans was introduced to ensure adaption of the radiotherapy treatment plan for all patients with significant anatomical changes during radiotherapy. Before 2013, the daily cone-beam CT scans were matched on the vertebra and anatomical changes were not evaluated systematically. To estimate the effect of tumor match and adaptive radiotherapy, 439 consecutive NSCLC patients treated with definitive chemo-radiotherapy (50-66 Gy/25-33 fractions, 2010-2018) were investigated retrospectively. They were split in two groups, pre-ART (before tumor match and adaptive radiotherapy, 184 patients), and ART (after tumor match and adaptive radiotherapy, 255 patients) and compared with respect to clinical, treatment-specific and dosimetric variables (χ2 tests, Mann Whitney U tests), progression, survival and radiation pneumonits (CTCAEv3). Progression-free and overall survival as well as radiation pneumonitis were compared with log-rank tests. Hazard ratios were estimated from Cox proportional hazard regression. RESULTS: No significant differences in stage (p = 0.36), histology (p = 0.35), PS (p = 0.12) and GTV volumes (p = 0.24) were observed. Concomitant chemotherapy was administered more frequently in the ART group (78%) compared to preART (64%), p < 0.001. Median[range] PTV volumes decreased from 456 [71;1262] cm3 (preART) to 270 [31;1166] cm3 (ART), p < 0.001, thereby significantly reducing mean doses to lungs (median, preART 16.4 [1.9;24.7] Gy, ART 12.1 [1.7;19.4] Gy, p < 0.001) and heart (median, preART 8.0 [0.1;32.1] Gy, ART 4.4 [0.1;33.9] Gy, p < 0.001). The incidence of RP at nine months decreased significantly with ART (50% to 20% for symptomatic RP (≥G2), 21% to 7% for severe RP (≥G3), 6% to 0.4% for lethal RP (G5), all p < 0.001). The two-year progression free survival increased from 22% (preART) to 30% (ART), while the overall survival increased from 43% (preART) to 56% (ART). The median overall survival time increased from 20 (preART) to 28 months (ART). CONCLUSION: Tumor match and adaptive radiotherapy significantly decreased radiation pneumonitis, while maintaining loco-regional control. Further, we observed a significantly improved progression-free and overall survival.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Møller DS, Lutz CM, Khalil AA, et al. Survival benefits for non-small cell lung cancer patients treated with adaptive radiotherapy. Radiother Oncol. 2022. PMID: 35121030. doi:10.1016/j.radonc.2022.01.039

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。